Patents by Inventor John R. Cappiello

John R. Cappiello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Coumarin compounds as receptor modulators with therapeutic utility
    Patent number: 9572792
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: February 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
    Publication number: 20150265573
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: June 3, 2015
    Publication date: September 24, 2015
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • Coumarin compounds as receptor modulators with therapeutic utility
    Patent number: 9073888
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: July 7, 2015
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • Compounds as receptor modulators with therapeutic utility
    Patent number: 8828973
    Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: September 9, 2014
    Assignee: Allergan, Inc.
    Inventors: Phong X. Nguyen, Todd M. Heidelbaugh, John R. Cappiello
  • NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
    Publication number: 20140221317
    Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 7, 2014
    Applicant: Allergan, Inc.
    Inventors: PHONG X. NGUYEN, TODD M. HEIDELBAUGH, John R. Cappiello
  • NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS
    Publication number: 20140171393
    Abstract: The present invention relates to novel aromatic thio derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 19, 2014
    Applicant: Allergan, Inc.
    Inventors: Phong X. Nguyen, John R. Cappiello, Todd M. Heidelbaugh
  • COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
    Publication number: 20120328661
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: October 20, 2010
    Publication date: December 27, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME
    Publication number: 20120196911
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
    Type: Application
    Filed: April 16, 2012
    Publication date: August 2, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael E. Garst, Larry A. Wheeler, John R. Cappiello
  • Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alphaadrenergic agonists and methods for using the same
    Patent number: 8178571
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: May 15, 2012
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael Garst, Larry A. Wheeler, John R. Cappiello
  • UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME
    Publication number: 20100298395
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
    Type: Application
    Filed: August 3, 2010
    Publication date: November 25, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael E. Garst, Larry A. Wheeler, John R. Cappiello
  • Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
    Patent number: 7829587
    Abstract: Substituted 2-aminotetralin derivatives as selective alpha 2B agonists can be incorporated in a pharmaceutical composition and can be used in methods of treating an alpha 2B receptor mediated diseases or conditions. The compounds are represented by Formula 1: wherein R1=H, methyl, ethyl, propyl, or cyclobutyl; R2=methyl or H; R3=pyridinyl X=C or O.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: November 9, 2010
    Assignee: Allergan, Inc.
    Inventors: John R. Cappiello, Dario G. Gomez, Ken Chow, Michael E. Garst, Daniel W. Gil, Larry A. Wheeler
  • Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
    Patent number: 7795292
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: September 14, 2010
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael E. Garst, Larry A. Wheeler, John R. Cappiello
  • SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS
    Publication number: 20100076194
    Abstract: The present invention provides compounds which are subtype selective antagonists of the alpha 2B adrenergic receptor and have no or weak antagonist activity at the other alpha adrenergic receptors. These compounds are useful as tool compounds and, in particular, as tool compounds for developing compounds useful in treating diseases that include but are not limited to chronic pain, visceral pain, corneal pain, neuropathic pain, glaucoma, ischemic neuropathies and other neurodegenerative diseases and conditions. These compounds are also useful as compounds for treating myocardial infarction and preventing acute coronary events. The compounds of this invention are 3-amino-1-thioxo or oxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles or substituted derivatives thereof.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 25, 2010
    Applicant: ALLERGAN, INC.
    Inventors: John R. CAPPIELLO, Ken CHOW, Todd M. HEIDELBAUGH, Janet A. TAKEUCHI, Michael E. GARST, Daniel W. GIL, Karen M. KEDZIE, John E. DONELLO